Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer Corrigendum in /10.3892/ol.2021.12572

Zhu,Lizhe; Ma,Nan; Wang,Bin; Zhou,Can; Yan,Yu; Wang,Ke; He,Jianjun; Ren,Yu

doi:10.3892/ol.2019.10277

Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer

Corrigendum in: /10.3892/ol.2021.12572

Authors:
- Lizhe Zhu
- Nan Ma
- Bin Wang
- Can Zhou
- Yu Yan
- Ke Wang
- Jianjun He
- Yu Ren
View Affiliations

Affiliations: Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: April 18, 2019 https://doi.org/10.3892/ol.2019.10277
Pages: 5469-5480
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The 21‑gene recurrence score (RS) predicts the prognosis of patients with estrogen receptor (ER)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative early‑stage breast cancer and the effectiveness of adding adjuvant chemotherapy on the basis of endocrine therapy to avoid excessive chemotherapy. The present study aimed to analyze clinicopathological characteristics and chemotherapeutic efficacy‑related target genes with the 21‑gene RS in hormone receptor‑positive early‑stage breast cancer in China. The prognostic value of chemotherapeutic efficacy‑related target genes was also examined. In addition, this study investigated the postoperative adjuvant therapeutic decision‑oriented role of 21‑gene RS in hormone receptor‑positive and lymph node‑negative early‑stage breast cancer. In the present retrospective study, 110 ER+/HER2‑ early‑stage breast cancer patients were tested with the 21‑gene RS. The analyses of clinicopathological characteristics and chemotherapeutic efficacy‑related target genes with the 21‑gene RS were performed using the χ2 test, the Wilcoxon rank‑sum test and binary logistic regression. Kaplan‑Meier survival plots were drawn in www.kmplot.com. Furthermore, the McNemar χ2 test was used to compare the changes of treatment decisions before and after the 21‑gene test. The median RS of 110 patients was 16 (range, 2‑47), and patients were categorized as low (59.1%), intermediate (34.5%) or high risk (6.4%). The results revealed that higher body mass index, invasive ductal carcinoma type, higher histological grade, luminal B molecular type and higher thymidylate synthetase (TYMS) and DNA topoisomerase IIα (TOP2A) gene expression levels were more likely to have a higher RS. Kaplan‑Meier plots suggested that expression of TYMS, tubulin β3 class III (TUBB3) and TOP2A genes was significantly associated with relapse‑free survival for ER+ breast cancer. Additionally, prior to 21‑gene RS testing, 61 patients (55%) were recommended adjuvant chemotherapy and endocrine therapy; however, following 21‑gene test, 32 patients (29%) were treated with only adjuvant endocrine therapy. TYMS, TUBB3 and TOP2A gene expression may have prognostic value for ER+ breast cancer. In addition, 21‑gene RS testing may aid to avoid excessive postoperative adjuvant chemotherapy.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Anderson BO and Jakesz R: Breast cancer issues in developing countries: An overview of the Breast Health Global Initiative. World J Surg. 32:2578–2585. 2008. View Article : Google Scholar : PubMed/NCBI
3	Zeng H, Zheng R, Zhang S, Zou X and Chen W: Female breast cancer statistics of 2010 in China: Estimates based on data from 145 population-based cancer registries. J Thorac Dis. 6:466–470. 2014.PubMed/NCBI
4	National Bureau of Statistics of China, . China Statistical Yearbook, 2010. China Statistics Press; Beijing: 2010
5	Salek R, Shahidsales S and Mozafari V: Changing pattern in the clinical presentation of breast cancer in the absence of a screening program over a period of thirty-three years in Iran. Breast. 28:95–99. 2016. View Article : Google Scholar : PubMed/NCBI
6	Somashekhar SP, Sepúlveda MJ, Puglielli S, Norden AD, Shortliffe EH, Rohit Kumar C, Rauthan A, Arun Kumar N, Patil P, Rhee K, et al: Watson for Oncology and breast cancer treatment recommendations: Agreement with an expert multidisciplinary tumor board. Ann Oncol. 29:418–423. 2018. View Article : Google Scholar : PubMed/NCBI
7	Gray J and Druker B: Genomics: The breast cancer landscape. Nature. 486:328–329. 2012. View Article : Google Scholar : PubMed/NCBI
8	Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004. View Article : Google Scholar : PubMed/NCBI
9	Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H and Toi M: Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat. 112:175–187. 2008. View Article : Google Scholar : PubMed/NCBI
10	Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC and Watson D: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 53:1084–1091. 2007. View Article : Google Scholar : PubMed/NCBI
11	Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 29:4273–4278. 2011. View Article : Google Scholar : PubMed/NCBI
12	Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American Society of Clinical Oncology, : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
13	Győrffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B and Pusztai L: Multigene prognostic tests in breast cancer: Past, present, future. Breast Cancer Res. 17:112015. View Article : Google Scholar : PubMed/NCBI
14	Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 24:3726–3734. 2006. View Article : Google Scholar : PubMed/NCBI
15	Paik S: Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist. 12:631–635. 2007. View Article : Google Scholar : PubMed/NCBI
16	Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB and Kaufman B: Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: A population-based study. Cancer. 112:731–736. 2008. View Article : Google Scholar : PubMed/NCBI
17	Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, et al Breast Cancer Intergroup of North America, : Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
18	Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
19	Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Albain KS, André F, Bergh J, et al Panel members, : Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
20	Tsunoda Y, Suzuki K, Tsunoda A, Takimoto M and Kusano M: Evaluation of 5-fluorouracil related genes in breast cancer to predict the effect of adjuvant therapy with oral fluorouracil derivatives. Oncol Rep. 23:771–777. 2010.PubMed/NCBI
21	Yu Z, Sun J, Zhen J, Zhang Q and Yang Q: Thymidylate synthase predicts for clinical outcome in invasive breast cancer. Histol Histopathol. 20:871–878. 2005.PubMed/NCBI
22	Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, et al: In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest. 28:172–180. 2010. View Article : Google Scholar : PubMed/NCBI
23	Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, et al: Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res. 14:4511–4516. 2008. View Article : Google Scholar : PubMed/NCBI
24	Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 9:338–350. 2009. View Article : Google Scholar : PubMed/NCBI
25	Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, Turley H, Wilner S, Harris AL and Talbot DC: Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res. 9:4682–4688. 2003.PubMed/NCBI
26	Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L and Győrffy B: miRpower: A web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 160:439–446. 2016. View Article : Google Scholar : PubMed/NCBI
27	Orucevic A, Bell JL, McNabb AP and Heidel RE: Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Res Treat. 163:51–61. 2017. View Article : Google Scholar : PubMed/NCBI
28	Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S and Lieberman N: The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res Treat. 140:83–92. 2013. View Article : Google Scholar : PubMed/NCBI
29	Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Ben-Baruch N, Bareket-Samish A, Geffen DB, Nisenbaum B, Isaacs K, Fried G, et al: Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: Evidence from a large prospectively designed registry. NPJ Breast Cancer. 3:332017. View Article : Google Scholar : PubMed/NCBI
30	Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, Soussan-Gutman L, Bareket-Samish A, Isaacs K, Rosengarten O, et al: Clinical outcomes in ER⁺ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: Evidence from a large prospectively designed registry. NPJ Breast Cancer. 3:322017. View Article : Google Scholar : PubMed/NCBI
31	Lee MH, Han W, Lee JE, Kim KS, Park H, Kim J, Bae SY, Shin HJ, Lee JW and Lee ES: The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea. Cancer Res Treat. 47:208–214. 2015. View Article : Google Scholar : PubMed/NCBI
32	Holt S, Bertelli G, Humphreys I, Valentine W, Durrani S, Pudney D, Rolles M, Moe M, Khawaja S, Sharaiha Y, et al: A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K. Br J Cancer. 108:2250–2258. 2013. View Article : Google Scholar : PubMed/NCBI
33	Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, et al: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 28:1671–1676. 2010. View Article : Google Scholar : PubMed/NCBI
34	Martínez Del Prado P, Alvarez-López I, Domínguez-Fernández S, Plazaola A, Ibarrondo O, Galve-Calvo E, Ancizar-Lizarraga N, Gutierrez-Toribio M, Lahuerta-Martínez A and Mar J: Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: Pooled analysis in 4 Basque Country university hospitals. Clinicoecon Outcomes Res. 10:189–199. 2018. View Article : Google Scholar : PubMed/NCBI
35	Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, et al: First prospective nulticenter Italian study on the impact of the 21-gene recurrence score in adjuvant clinical decisions for patients with ER positive/HER2 negative breast cancer. Oncologist. 23:297–305. 2018. View Article : Google Scholar : PubMed/NCBI
36	Yamauchi H, Nakagawa C, Takei H, Chao C, Yoshizawa C, Yagata H, Yoshida A, Hayashi N, Hell S and Nakamura S: Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer. Clin Breast Cancer. 14:191–197. 2014. View Article : Google Scholar : PubMed/NCBI
37	Eiermann W, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, et al: The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol. 24:618–624. 2013. View Article : Google Scholar : PubMed/NCBI